Friday, July 10, 2026

Drug profile · INN

betrixaban

betrixaban (DEXXIENCE) is a coagulation factor x inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: refused Blood and blood forming organs (B01) B01AF
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — betrixaban
US status
approved
Class
Blood and blood forming organs (B01)
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

betrixaban (DEXXIENCE) is a coagulation factor x inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN betrixaban
Brand DEXXIENCE
Mechanism Coagulation factor X inhibitor
Target Coagulation factor X
Therapeutic class Blood and blood forming organs (B01)
Route ORAL
Formulation CAPSULE
ATC code B01AF

Mechanism of action

Coagulation factor X inhibitor

Primary target: Coagulation factor X

Approval history

Authority Status Date
FDA approved
EMA refused

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Frequently asked questions

What is betrixaban?

betrixaban (DEXXIENCE) is a coagulation factor x inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for betrixaban?

DEXXIENCE is a marketed brand name for betrixaban. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of betrixaban?

betrixaban has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.